108606009: Salmeterol xinafoate (substance)

SNOMED CT Concept\Substance\...

\Substance categorized by disposition\Receptor agonist\Adrenergic receptor agonist\Beta adrenergic receptor agonist\Substance with beta-2 adrenergic receptor agonist mechanism of action (substance)\Salmeterol xinafoate

\A grouper concept for substances that are used in medicinal products for medical treatment, and also psychoactive substances that have few or no legitimate medical uses or that are not legally available to the person using them.\Autonomic agent (substance)\Sympathomimetic agent (substance)\Adrenergic receptor agonist\Beta adrenergic receptor agonist\Substance with beta-2 adrenergic receptor agonist mechanism of action (substance)\Salmeterol xinafoate
\A grouper concept for substances that are used in medicinal products for medical treatment, and also psychoactive substances that have few or no legitimate medical uses or that are not legally available to the person using them.\Respiratory system agent (substance)\Bronchodilator (substance)\Substance with beta-2 adrenergic receptor agonist mechanism of action (substance)\Salmeterol xinafoate

\Substance categorised by structure\Chemical\Chemical categorized by structure (substance)\Organic compound\Organic cyclic compound\Substance with phenol structure\Salmeterol xinafoate

Status: current, Not sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Jan 2002. Module: SNOMED CT core

Descriptions:

Id Description Lang Type Status Case? Module

173140019 Salmeterol xinafoate en Synonym (core metadata concept) Active Entire term case insensitive (core metadata concept) SNOMED CT core

602650010 Salmeterol xinafoate (substance) en Fully specified name Active Entire term case insensitive (core metadata concept) SNOMED CT core

2605941000005111 Salmeterolxinafoat da Synonym (core metadata concept) Active Entire term case insensitive (core metadata concept) Danish module (core metadata concept)

Expanded Value Set

Outbound Relationships	Type	Target	Active	Characteristic	Refinability	Group	Values
Salmeterol xinafoate	Is a	Product containing salmeterol (medicinal product)	false	Inferred relationship	Some
Salmeterol xinafoate	Is a	Salmeterol (substance)	false	Inferred relationship	Some
Salmeterol xinafoate	This attribute specifies the behavior that a substance will exhibit or participate in, given the appropriate context.	Beta adrenergic receptor agonist (disposition)	false	Inferred relationship	Some
Salmeterol xinafoate	This attribute specifies the behavior that a substance will exhibit or participate in, given the appropriate context.	Beta-2 adrenergic receptor agonist	true	Inferred relationship	Some
Salmeterol xinafoate	This attribute indicates that the concept is a structural modification of another concept, and that the substance's intrinsic physicochemical properties remain unchanged.	Salmeterol (substance)	true	Inferred relationship	Some
Salmeterol xinafoate	Is a	Substance with beta-2 adrenergic receptor agonist mechanism of action (substance)	true	Inferred relationship	Some
Salmeterol xinafoate	Is a	Substance with phenol structure	true	Inferred relationship	Some

Inbound Relationships	Type	Active	Source	Characteristic	Refinability	Group
salmeterolxinafoat 21 µg aerosolspray	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Salmeterol xinafoate	Inferred relationship	Some
salmeterolxinafoat 50 µg pulver	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Salmeterol xinafoate	Inferred relationship	Some
salmeterolxinafoat 38,06 µg inhalator	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Salmeterol xinafoate	Inferred relationship	Some
Product containing fluticasone and salmeterol (medicinal product)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Salmeterol xinafoate	Inferred relationship	Some
Fluticasone propionate + salmeterol xinafoate 250mcg/50mcg powder for oral inhalation	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Salmeterol xinafoate	Inferred relationship	Some
Fluticasone propionate + salmeterol xinafoate 500mcg/50mcg powder for oral inhalation	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Salmeterol xinafoate	Inferred relationship	Some
Fluticasone propionate + salmeterol xinafoate 100mcg/50mcg powder for oral inhalation (product)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Salmeterol xinafoate	Inferred relationship	Some
salmeterol 50 µg + fluticasonpropionat 100 µg indåndingsudløst tørpulverinhalator	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Salmeterol xinafoate	Inferred relationship	Some
salmeterol 25 µg + fluticasonpropionat 250 µg CFC-fri inhalator	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Salmeterol xinafoate	Inferred relationship	Some
salmeterol 25 µg + fluticasonpropionat 50 µg CFC-fri inhalator	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Salmeterol xinafoate	Inferred relationship	Some
salmeterol 50 µg + fluticasonpropionat 0500 µg indåndingsudløst tørpulverinhalator	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Salmeterol xinafoate	Inferred relationship	Some
salmeterol 25 µg + fluticasonpropionat 125 µg CFC-fri inhalator	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Salmeterol xinafoate	Inferred relationship	Some
salmeterol 50 µg + fluticasonpropionat 250 µg indåndingsudløst tørpulverinhalator	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Salmeterol xinafoate	Inferred relationship	Some
Salmeterol (as salmeterol xinafoate) 25 microgram/actuation pressurized suspension for inhalation	The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration).	True	Salmeterol xinafoate	Inferred relationship	Some	1
Salmeterol (as salmeterol xinafoate) 50 microgram/actuation powder for inhalation	The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration).	True	Salmeterol xinafoate	Inferred relationship	Some	1
Fluticasone propionate 50 microgram and salmeterol (as salmeterol xinafoate) 25 microgram/actuation pressurized suspension for inhalation	The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration).	False	Salmeterol xinafoate	Inferred relationship	Some	2
Fluticasone propionate 100 microgram and salmeterol (as salmeterol xinafoate) 50 microgram/actuation powder for inhalation	The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration).	True	Salmeterol xinafoate	Inferred relationship	Some	1
Fluticasone propionate 500 microgram and salmeterol (as salmeterol xinafoate) 50 microgram/actuation powder for inhalation	The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration).	True	Salmeterol xinafoate	Inferred relationship	Some	1
Fluticasone propionate 250 microgram and salmeterol (as salmeterol xinafoate) 25 microgram/actuation pressurized suspension for inhalation	The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration).	True	Salmeterol xinafoate	Inferred relationship	Some	1
Fluticasone propionate 125 microgram and salmeterol (as salmeterol xinafoate) 25 microgram/actuation pressurized suspension for inhalation	The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration).	True	Salmeterol xinafoate	Inferred relationship	Some	1
Fluticasone propionate 250 microgram and salmeterol (as salmeterol xinafoate) 50 microgram/actuation powder for inhalation	The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration).	True	Salmeterol xinafoate	Inferred relationship	Some	1
Product containing precisely salmeterol (as salmeterol xinafoate) 21 microgram/1 actuation conventional release solution for inhalation (clinical drug)	The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration).	True	Salmeterol xinafoate	Inferred relationship	Some	1
Fluticasone propionate 50 microgram and salmeterol (as salmeterol xinafoate) 25 microgram/actuation pressurized suspension for inhalation	The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration).	True	Salmeterol xinafoate	Inferred relationship	Some	1

This concept is not in any reference sets

Back to Start

Id	Description	Lang	Type	Status	Case?	Module
173140019	Salmeterol xinafoate	en	Synonym (core metadata concept)	Active	Entire term case insensitive (core metadata concept)	SNOMED CT core
602650010	Salmeterol xinafoate (substance)	en	Fully specified name	Active	Entire term case insensitive (core metadata concept)	SNOMED CT core
2605941000005111	Salmeterolxinafoat	da	Synonym (core metadata concept)	Active	Entire term case insensitive (core metadata concept)	Danish module (core metadata concept)